Anti-Human XEDAR

Pricing & Details

Product No.X102
Protein
XEDAR
Formats AvailableView All
Product Type
Polyclonal Antibody
Alternate Names
X-Linked Ectodysplasin-A2 Receptor, (Ectodysplasin A2 Receptor) EDA2R, EDA-A2R, EDAA2R, TNFRSF27
Applications
IHC FFPE
,
WB
Prod No.
Size
Price
Avail.
Qty
Add to cart
X102-20ug
20 µg
$195.00
In stock
Max:
Min: 1
Step: 1
X102-0.1 mg
0.1 mg
$397.00
In stock
Max:
Min: 1
Step: 1
Bulk quantities available. Contact us for pricing.

Data

Antibody Details

Product Details

Reactivity Species
Human
Host Species
Rabbit
Product Concentration
0.5 mg/ml
Formulation
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Storage and Handling
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day Ambient
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Rabbit Anti-Human X-Linked Ectodysplasin-A2 Receptor (XEDAR) recognizes Human XEDAR. This polyclonal antibody was purified using affinity chromatography.
Background
XEDAR (X-linked Ectodysplasin A2 Receptor) is a recently isolated member of the tumor necrosis factor receptor family that is highly expressed during embryonic development and induces apoptosis.1 XEDAR is a receptor for Ectodysplasin-A2 (EDA-A2) which may be a promising agent for the gene therapy of osteosarcoma.2

Antigen Details

Protein
PubMed

References & Citations

1. Chaudhary, PM. et al. (2004) J Biol Chem. 279: 41873
2. Chaudhary, PM. et al. (2007) Cancer Gene Ther. 14: 927
IHC
General Western Blot Protocol
Prod No.
Description
X102
X111
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy. Ok